drugset / Trial / NCT06487052

Evaluation of the Standard Catheter-directed Thrombolysis Effectiveness in Intermediate-High-Risk Pulmonary Embolism Patients

NCT06487052

RandomizedParallel-groupOpen-labelTreatment

Summary

A single-center, open-label, randomized comparative study of two treatment strategies in patients with intermediate-high-risk acute pulmonary embolism (PE). Patients will be randomized in a 1:1 ratio to standard anticoagulant therapy or standard catheter-directed thrombolysis (SСDT) with a low dose of alteplase, followed by evaluation of short- and long-term efficacy and safety in each group

Timeline

Start
2024-01-10
Primary completion
2027-01
Completion
2027-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Alteplase Protein / enzyme biologic 10 mg Other
Subject Alteplase Protein / enzyme biologic 20 mg Other
Background UFH Unknown

Indications